In vitro and in vivo evaluation of the efficacy of nanoformulation of siRNA as an adjuvant to improve the anticancer potential of cisplatin

Experimental and Molecular Pathology

Volumn 94, Issue 1, 2013, Pages 137-147

  Koganti, Spandana ^a   Jagani, Hitesh V ^a   Palanimuthu, Vasanth Raj ^a   Mathew, Jesil A ^a   Rao, Mallikarjuna C ^a   Rao, J Venkata ^a  

^a MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

Bcl 2 and cisplatin; Nanoformulations; Poly(d,l lactide co glycolide); SiRNA

Indexed keywords

CISPLATIN; PROTEIN BCL 2; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; NEOPLASM; NEPHROTOXICITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; HELA CELLS; HEP G2 CELLS; HUMANS; MICE; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; THIONUCLEOTIDES;

MUS;

EID: 84870935425     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2012.10.007     Document Type: Article

References (33)

1. Abdelrahim M., Safe S., Baker C., Abudayyeh A. RNAi and cancer: implications and applications. International Journal of RNA and Gene Targeting Research 2006, 2:136-142.
2. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998, 281:1322-1328.
3. Burnette W.N. "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Analytical Biochemistry 1981, 112:195-203.
4. Chandra J., Kaufmann S.H. Apoptotic pathways in cancer progression and treatment. Signal Transduction and Human Disease 2003, 143-170.
5. Corso S., Comoglio P.M., Giordano S. Cancer therapy: can the challenge be MET?. Trends in Molecular Medicine 2005, 11:284-292.
6. Cory S., Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nature Reviews. Cancer 2002, 2:647-656.
7. Cun D., Foged C., Yang M., Frakjar S., Nielsen H.M. Preparation and characterization of poly(dl-lactide-co-glycolide) nanoparticles for siRNA delivery. International Journal of Pharmaceutics 2009, 390:70-75.
8. Daugaard G., Abildgaard U. Cisplatin nephrotoxicity. Cancer Chemotherapy and Pharmacology 1989, 25:1-9.
9. Denizot F., Lang R. Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. Journal of Immunological Methods 1986, 89:271-277.
10. Dhamija, I., Kumar, N., Manjula, S.N., Parihar, V., Setty, M.M., Pai, K.S.R., in press. Preliminary evaluation of in vitro cytotoxicity and in vivo antitumor activity of Premna herbacea Roxb. in Ehrlich ascites carcinoma model and Dalton's lymphoma ascites model. Experimental and Toxicologic Pathology. http://dx.doi.org/10.1016/j.etp.2011.08.009.
11. Fuertes M.A., Alonso C., Perez J.M. Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chemical Reviews 2003, 103:645-662.
12. Gopal M., Shenoy S., Doddamani L.S. Antitumor activity of 4-amino and 8-methyl-4- (3diethylamino propylamino) pyramided [4',5':4,5] thieno (2,3-b) quinolines. Journal of Photochemistry and Photobiology B 2003, 72:69-78.
13. Hanahan D. The hallmarks of cancer. Cell 2000, 100:57-70.
14. Hanigan M.H., Devarajan P. Cisplatin nephrotoxicity: molecular mechanisms. Cancer Therapy 2003, 1:47.
15. Jagani H.V., Josyula V.R., Hariharapura R.C., Palanimuthu V.R., Gang S.S. Nanoformulation of siRNA silencing Bcl-2 gene and its implication in cancer therapy. Arzneimittel-Forschung 2011, 61:577-586.
16. Kerbel R.S. A cancer therapy resistant to resistance. Nature 1997, 390:335-336.
17. Lanciotti R.S., Calisher C.H., Gubler D.J., Chang G.J., Vorndam A.V. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. Journal of Clinical Microbiology 1992, 30:545-551.
18. Manjula S.N., Kenganora M., Parihar V.K., Kumar S., Nayak P.G., Kumar N., Ranganath Pai K.S., Rao C.M. Antitumor and antioxidant activity of Polyalthia longifolia stem bark ethanol extract. Pharmaceutical Biology 2010, 48:690-696.
19. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods 1983, 65:55-63.
20. Mukherjee K.L. Medical Laboratory Technology 1988, Tata McGraw-Hill Education.
21. Mullis K.B. Process for Amplifying Nucleic Acid Sequences 1987, Google Patents.
22. Mullis K.B., Faloona F.A., Scharf S.J., Saiki R.K., Horn G.T., Erlich H. Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. Cold Spring Harbor Symposia on Quantitative Biology 1986, 51:263-273.
23. Nakagawara A., Nathan C.F. A simple method for counting adherent cells: application to cultured human monocytes, macrophages and multinucleated giant cells. Journal of Immunological Methods 1983, 56:261-268.
24. Panyam J., Labhasetwar V. Dynamics of endocytosis and exocytosis of poly(d,l-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharmaceutical Research 2003, 20:212-220.
25. Panyam J., Sahoo S.K., Prabha S., Bargar T., Labhasetwar V. Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(d,l-lactide-co-glycolide) nanoparticles. International Journal of Pharmaceutics 2003, 262:1-11.
26. Reed J.C. Dysregulation of apoptosis in cancer. Journal of Clinical Oncology 1999, 17:2941-2950.
27. Reed J.C. Apoptosis-targeted therapies for cancer. Cancer Cell 2003, 3:17-21.
28. Safirstein R., Winston J., Goldstein M., Moel D., Dikman S., Guttenplan J. Cisplatin nephrotoxicity. American Journal of Kidney Diseases 1986, 8:356-361.
29. Steenbergen C., Hill M.L., Jennings R.B. Cytoskeletal damage during myocardial ischemia: changes in vinculin immunofluorescence staining during total in vitro ischemia in canine heart. Circulation Research 1987, 60:478-486.
30. Tan F.L., Yin J.Q. Application of RNAi to cancer research and therapy. Frontiers in Bioscience 2005, 10:1946-1960.
31. World Health, O. WHO Handbook for Reporting Results of Cancer Treatment 1979, World Health Organization.
32. Yao X., Panichpisal K., Kurtzman N., Nugent K. Cisplatin nephrotoxicity: a review. The American Journal of the Medical Sciences 2007, 334:115-123.
33. Zeier M., Fehrenbach P., Geberth S., Moehring K., Waldherr R., Ritz E. Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney International 1992, 42:1259-1265.